Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 196

1.

Sunitinib in the treatment of metastatic renal cell carcinoma.

Schmid TA, Gore ME.

Ther Adv Urol. 2016 Dec;8(6):348-371. Review.

2.

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma.

Rini BI, McDermott DF, Hammers H, Bro W, Bukowski RM, Faba B, Faba J, Figlin RA, Hutson T, Jonasch E, Joseph RW, Leibovich BC, Olencki T, Pantuck AJ, Quinn DI, Seery V, Voss MH, Wood CG, Wood LS, Atkins MB.

J Immunother Cancer. 2016 Nov 15;4:81.

3.

Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma.

Rodriguez-Vida A, Strijbos M, Hutson T.

ESMO Open. 2016 May 25;1(3):e000013. Review.

4.

Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma.

Crusz SM, Tang YZ, Sarker SJ, Prevoo W, Kiyani I, Beltran L, Peters J, Sahdev A, Bex A, Powles T, Gerlinger M.

BMC Med. 2016 Nov 14;14(1):185.

5.

A Prospective Multicenter Trial of the Efficacy and Tolerability of Neoadjuvant Sunitinib for Inoperable Metastatic Renal Cell Carcinoma.

Kim SH, Seo SI, Lee HM, Choi HY, Jeon SH, Lee HL, Kwon TG, Kim YJ, Kim WJ, Chung J.

J Korean Med Sci. 2016 Dec;31(12):1983-1988. doi: 10.3346/jkms.2016.31.12.1983.

6.

Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2.

Gill DM, Stenehjem DD, Parikh K, Merriman J, Sendilnathan A, Agarwal AM, Hahn AW, Gupta S, Tantravahi SK, Samlowski WE, Agarwal N.

Ecancermedicalscience. 2016 Sep 29;10:676.

7.

Safety and efficacy of sunitinib in patients from Latin America: subanalysis of an expanded access trial in metastatic renal cell carcinoma.

Barrios CH, Herchenhorn D, Chacón M, Cabrera-Galeana P, Sajben P, Zhang K.

Onco Targets Ther. 2016 Sep 23;9:5839-5845.

8.

Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy.

Buti S, Leonetti A, Dallatomasina A, Bersanelli M.

Core Evid. 2016 Sep 1;11:23-36. doi: 10.2147/CE.S98687. Review.

10.

Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience.

Coelho RC, Reinert T, Campos F, Peixoto FA, de Andrade CA, Castro T, Herchenhorn D.

Int Braz J Urol. 2016 Jul-Aug;42(4):694-703. doi: 10.1590/S1677-5538.IBJU.2015.0226.

11.

Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 IU/L.

Liu R, Cao J, Gao X, Zhang J, Wang L, Wang B, Guo L, Hu X, Wang Z.

Tumour Biol. 2016 Oct;37(10):14083-14088.

12.

Medical treatment of renal cancer: new horizons.

Greef B, Eisen T.

Br J Cancer. 2016 Aug 23;115(5):505-16. doi: 10.1038/bjc.2016.230. Review.

14.

Insulin-like growth factor-1 signaling in renal cell carcinoma.

Tracz AF, Szczylik C, Porta C, Czarnecka AM.

BMC Cancer. 2016 Jul 12;16:453. doi: 10.1186/s12885-016-2437-4.

15.

Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients.

Ordu Ç, Pilanci KN, Avcı N, Yıldız İ, Alço G, Demirhan Ö, Köksal ÜI, Elbüken F, Tecimer C, Demir G.

Contemp Oncol (Pozn). 2016;20(2):147-52. doi: 10.5114/wo.2016.60069.

16.

Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry.

De Groot S, Sleijfer S, Redekop WK, Oosterwijk E, Haanen JB, Kiemeney LA, Uyl-de Groot CA.

BMC Cancer. 2016 Jun 11;16:364. doi: 10.1186/s12885-016-2395-x.

17.

A simple prognostic model for overall survival in metastatic renal cell carcinoma.

Assi HI, Patenaude F, Toumishey E, Ross L, Abdelsalam M, Reiman T.

Can Urol Assoc J. 2016 Mar-Apr;10(3-4):113-9. doi: 10.5489/cuaj.3351.

18.

Model-based genotype-phenotype mapping used to investigate gene signatures of immune sensitivity and resistance in melanoma micrometastasis.

Santos G, Nikolov S, Lai X, Eberhardt M, Dreyer FS, Paul S, Schuler G, Vera J.

Sci Rep. 2016 Apr 26;6:24967. doi: 10.1038/srep24967.

19.

Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives.

Narayan V, Haas NB.

Int J Nephrol Renovasc Dis. 2016 Mar 29;9:65-72. doi: 10.2147/IJNRD.S83874. Review.

20.

Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy.

Kawano Y, Takahashi W, Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, Tsukamoto T, Azuma H, Matsubara A, Nishimura K, Nakamura T, Ogawa O, Naito S.

Cancer Sci. 2016 Jul;107(7):1013-7. doi: 10.1111/cas.12951.

Items per page

Supplemental Content

Support Center